16 results about "Anti-malarials" patented technology

The present disclosure provides anti-circumsporozoite (CSP) antibodies, compositions containing such antibodies, methods for producing the disclosed antibodies, and methods for using them to treat or prevent malaria, as well as methods for selecting antibodies as anti-malaria therapeutic antibodies.

This invention belongs to the field of organic synthetic chemistry technology, specifically relating to a selenium-based indoloquinazoline derivative, its preparation method, and its application, comprising: in an organic solvent, using aromatic amine compounds, malononitrile, and diselenoether as raw materials, in the presence of a palladium catalyst and an organic base, at 90°C... o The reaction was carried out under C conditions with stirring to obtain a selenyl indoline quinazoline derivative. This method features mild reaction conditions, simple operation, high yield, and good functional group compatibility, conforming to the principles of green chemistry. Furthermore, the selenyl indoline quinazoline derivative provided by this invention exhibits good inhibitory activity against Plasmodium, providing a drug lead compound for the development of novel antimalarial drugs and holding significant importance for the prevention and / or treatment of malaria.

The present invention provides novel mitochondria-targeted Atovaquone compounds (Mito-ATO), a mitochondria-targeted derivative of Atovaquone, and methods of using such compounds. Methods of treating cancer using mito-ATO are also provided. Methods of enhancing an anti-tumor immune response by administering mito-ATO are further provided.

The present invention provides novel mitochondria-targeted Atovaquone compounds (Mito-ATO), a mitochondria-targeted derivative of Atovaquone, and methods of using such compounds. Methods of treating cancer using mito-ATO are also provided. Methods of enhancing an anti-tumor immune response by administering mito-ATO are further provided.

To provide a new antimalarial agent that achieves a balance between strong antimalarial activity and low cytotoxicity.SOLUTION: An antimalarial agent comprising an ethanol extract and / or a methanol extract of at least one plant selected from the group consisting of Ficus hispida, Streblus asper, Boerhavia repens, Clerodendrum viscosum, Amaranthus spinosus, and Mussaenda corymbosa.SELECTED DRAWING: None

Disclosed is a use of artemether in preventing and treating Alzheimer's disease. Artemether is a safe and effective compound for treatment against malaria. Artemether activates an AMPK signaling pathway in the brain of a transgenic mouse model of Alzheimer's disease, improves learning and memory abilities in the mouse model, reduces neuron apoptosis in the brain, improves function of choline acetyltransferase, inhibits activity of glial cells, and reduces amyloid plaque deposition, neurofibrillary tangle, and neuron loss, thereby providing an experimental basis for clinical research on the treatment of Alzheimer's disease.

The present application relates to a preparation of a 7,7'-epoxy lignan compound and its application in preparing anti-malaria products, and belongs to the field of traditional Chinese medicine and natural medicine pharmacy. The anti-malaria medicine with the compound as an active ingredient. The present application expands the medicinal value of 7,7'-epoxy lignan compounds in Rhodiola henryi.

This invention relates to the field of pharmaceutical biotechnology, providing the application of aminoquinoline compounds (such as hydroxychloroquine and chloroquine) in the preparation of drugs for treating hyperparathyroidism. These compounds restore the expression of calcium-sensitive receptors (CaSRs) on the cell membrane surface by inhibiting the lysosomal degradation pathway of CaSRs in parathyroid cells. Experiments have confirmed that 4-aminoquinoline compounds, used alone or in combination with calcimimetics (such as cinacalcet), significantly reduce serum PTH and calcium levels in a model of refractory secondary hyperparathyroidism (SHPT) and inhibit glandular hyperplasia. In particular, the combination therapy regimen exhibits a significant synergistic effect, effectively reversing calcimimetics resistance. This invention is the first to discover a novel use for the antimalarial / antirheumatic drug hydroxychloroquine in the treatment of hyperparathyroidism, realizing a new use for an existing drug; and providing a safe and effective new drug treatment strategy for clinically refractory SHPT.

This disclosure relates to a compound represented by formula I:(I) and a method for treating malaria parasitic infection, the method comprising administering the compound represented by formula I or a pharmaceutically acceptable salt thereof to a person in need of such treatment. [Formula 1] TIFF2026520957000151.tif23115

The invention discloses a pyrimidine-hydroxamic acid compound as well as a preparation method and application thereof. The compound has a general formula as shown in a formula I. The compound can be used as a small-molecule inhibitor of histone deacetylase (HDAC), has strong anti-malaria activity, has a remarkable killing effect on various wild and drug-resistant plasmodium, and has the potential of being developed into an anti-malaria drug with a novel action mechanism.

The present invention recognizes that there is a need for the prophylaxis or treatment of COVID and COVID-19. A first aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using various pharmaceutical compositions. A second aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using combinations of antimalarial drugs and antiviral drugs. A third aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using nanoparticle formulations that include pharmaceutical compositions. A fourth aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using combinations of various pharmaceutical compositions. A fifth aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using a polio vaccine and pharmaceutical compositions.

The present invention is related to new derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to dihydroisoquinoline derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation.

This invention relates to a 6- O -L-arabinopyranosyl- β The preparation of β-D-glucopyranoside and its application in the preparation of antimalarial products belong to the field of traditional Chinese medicine and natural drug pharmaceuticals. Compound 6- of this invention... O -L-arabinopyranosyl- β This invention relates to an antimalarial drug with β-D-glucopyranoside as the active ingredient. It expands the application of aromatic disaccharide compounds 6- from *Hydrangea macrophylla*. O -L-arabinopyranosyl- β The medicinal value of D-glucopyranoside.

The present disclosure provides anti-cyclosporozoite (CSP) antibodies, compositions comprising such antibodies. Methods of producing the disclosed antibodies and methods of treating or preventing malaria using the antibodies are also disclosed. Methods of selecting antibodies as anti-malarial therapeutic antibodies are also disclosed.

This invention provides methods for treating acute respiratory distress syndrome (ARDS), including ARDS associated with respiratory viral infections. [Solution] Administer plasma kallikrein (pKal) inhibitors such as anti-pKal antibodies as inhibitors of the contact activation pathway. Immunomodulators such as IL-6R inhibitors, antiviral agents such as lopinavir, ritonavir, interferon beta, umfenovir, and remdesivir, antimalarial agents such as chloroquine, and / or inhibitors of the contact activation pathway such as C1 inhibitors, pKal inhibitors, and bradykinin receptor antagonists may be administered to the patient as additional therapeutic agents.